Dr. Linda Vahdat and her colleagues are very excited to be involved in the development of glembatumuma vedotin as it has the potential to be among the very first drugs for triple negative breast cancer.
The Weill Cornell Breast Center recently opened a new triple negative breast cancer program. The study is for women diagnosed with triple negative breast cancer. There is an urgent need to develop new, targeted treatments for triple negative breast cancer. Through our Program, we plan to integrate research, treatment and education to accelerate and identify new targets and strategies to treat and cure triple negative breast cancer.
For more information about the study, please call Margie for a consult appointment with Dr. Vahdat at (212)-821-0644 and contact Naomi for more information at (212)-821-0984 or firstname.lastname@example.org.
“From a patient perspective this study requires very little of participants. I think that for post-treatment women like me the opportunity to participate so easily in cutting edge research at a world-class institution like WCMC is a great way to ‘pay it forward’ in appreciation to all those women whose participation in past clinical trials directly benefited us in terms of improvements in how breast cancer is treated. This is an exceedingly rare opportunity!”
– Triple Negative Breast Cancer Program participant
Researchers at Weill Cornell Medical College have recently published the results of a Phase II clinical trial conducted at the Weill Cornell Breast Center. The results show that an anti-copper drug called tetrathiomolybdate (TM) that disables the ability of bone marrow cells from setting up a “home” in organs to receive and nurture migrating cancer tumor cells has shown surprising benefit in treating high-risk triple-negative breast cancer, one of the most difficult-to-treat forms of cancer.
The median survival for metastatic triple-negative breast cancer patients is historically nine months. However, the results of the study, recently published in the Annals of Oncology, show that if patients at high-risk of relapse with no current visible breast cancer are copper depleted, it results in a prolonged period of time with no cancer recurrence. Only two of 11 study participants with a history of advanced triple-negative breast cancer relapsed within 10 months after treatment with tetrathiomolybdate (TM).
“These study findings are very promising and potentially a very exciting advance in our efforts to help women who are at the highest risk of recurrence,” says the study’s senior investigator, Dr. Linda Vahdat, director of the Breast Cancer Research Program, chief of the Solid Tumor Service and Professor of Medicine at Weill Cornell Medical College.
Four of the study participants with a history of metastatic triple-negative breast cancer have had long-term benefit remaining disease free for between three and five and a half years.
“The anti-copper compound appears to be keeping tumors that want to spread in a dormant state,” reports Dr. Vahdat. “We believe one of the important ways it works is by affecting the tumor microenvironment, specifically the bone marrow-derived cells that are critical for metastasis progression.”
In addition, study participants with other forms of high-risk for relapse breast cancers — either stage 3 or stage 4 — without evidence of disease after treatment have also fared well. The progression-free survival rate among these 29 patients in the study has been 85 percent, to date.
“As good as these interim findings look to us, we cannot talk about significant benefit until we compare TM treatment to other therapies,” she says. Dr. Vahdat expects to launch a phase III randomized clinical trial in the near future.
This research is a report of the first 40 patients. The clinical trial, which began in 2007, has been expanded many times and now includes 60 patients, more than half of who have triple-negative breast cancer.